- Home
- GMAB vs FTAI Comparison
GMAB vs FTAI Comparison
Compare GMAB & FTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- FTAI
- Stock Information
- Founded
- GMAB 1999
- FTAI 2011
- Country
- GMAB Denmark
- FTAI United States
- Employees
- GMAB N/A
- FTAI N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- FTAI Misc Corporate Leasing Services
- Sector
- GMAB Health Care
- FTAI Industrials
- Exchange
- GMAB Nasdaq
- FTAI Nasdaq
- Market Cap
- GMAB 13.7B
- FTAI 12.7B
- IPO Year
- GMAB N/A
- FTAI 2015
- Fundamental
- Price
- GMAB $21.88
- FTAI $113.59
- Analyst Decision
- GMAB Buy
- FTAI Strong Buy
- Analyst Count
- GMAB 7
- FTAI 12
- Target Price
- GMAB $37.80
- FTAI $171.83
- AVG Volume (30 Days)
- GMAB 1.5M
- FTAI 2.4M
- Earning Date
- GMAB 08-07-2025
- FTAI 07-29-2025
- Dividend Yield
- GMAB N/A
- FTAI 1.06%
- EPS Growth
- GMAB 276.80
- FTAI N/A
- EPS
- GMAB 18.36
- FTAI 0.25
- Revenue
- GMAB $3,230,902,140.00
- FTAI $1,910,287,000.00
- Revenue This Year
- GMAB $747.74
- FTAI $36.95
- Revenue Next Year
- GMAB $14.81
- FTAI $20.71
- P/E Ratio
- GMAB $1.19
- FTAI $446.92
- Revenue Growth
- GMAB 25.43
- FTAI 58.55
- 52 Week Low
- GMAB $17.24
- FTAI $75.06
- 52 Week High
- GMAB $28.56
- FTAI $181.64
- Technical
- Relative Strength Index (RSI)
- GMAB 56.89
- FTAI 45.31
- Support Level
- GMAB $21.10
- FTAI $111.29
- Resistance Level
- GMAB $21.90
- FTAI $119.49
- Average True Range (ATR)
- GMAB 0.39
- FTAI 4.41
- MACD
- GMAB 0.11
- FTAI -0.17
- Stochastic Oscillator
- GMAB 79.95
- FTAI 46.42
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About FTAI FTAI Aviation Ltd.
FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.